Patents Issued in February 1, 2024
-
Publication number: 20240034998Abstract: An object of the present invention is to easily obtain a large number of cardiomyocyte spheroids from cardiomyocytes separated into single cells. The present invention provides a method of producing a cardiomyocyte spheroid, the method comprising a step of culturing cardiomyocytes separated into single cells while stirring liquid in a container in which the cardiomyocytes are suspended, thereby causing aggregation of the cells.Type: ApplicationFiled: September 29, 2023Publication date: February 1, 2024Applicant: KANEKA CORPORATIONInventors: Terasu KAWASHIMA, Yoshikazu KAWAI, Sho KAMBAYASHI
-
Publication number: 20240034999Abstract: Provided are methods and compositions for inducing the reprogramming of a non-pluripotent cell using a small molecule supported vector system to provide an iPSC having desirable properties with a high efficiency. Also provided are reprogramming cells and iPSC populations or clonal cell lines using the provided reprogramming methods and compositions. Further provided are compositions and methods for maintaining and preserving iPSCs while achieving genomic stability of the cells.Type: ApplicationFiled: October 1, 2021Publication date: February 1, 2024Inventors: Yi-Shin LAI, Bahram VALAMEHR, Ramzey ABUJAROUR, Hui-Ting HSU
-
Publication number: 20240035000Abstract: This invention is intended to suppress cell death occurring at the time of transition of adherent culture of pluripotent stem cells to suspension culture thereof. Pluripotent stem cells are subjected to adherent culture in a liquid medium comprising a PKC? inhibitor and a TNKS inhibitor and then to suspension culture.Type: ApplicationFiled: December 7, 2021Publication date: February 1, 2024Applicants: KANEKA CORPORATION, RIKENInventors: Sho KAMBAYASHI, Yohei HAYASHI, Mami TAKASAKI
-
Publication number: 20240035001Abstract: A bacteriophage which consists of the nucleotide sequence represented by SEQ ID NO: 1 or a nucleotide sequence having 90% or more identity thereto, as its genome, is capable of infecting and lysing a diabetes-inducible bacterium belonging to Fusimonas intestini,containing a cyclic single-stranded DNA.Type: ApplicationFiled: July 21, 2023Publication date: February 1, 2024Applicants: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, AJINOMOTO CO., INC.Inventors: Keishi KAMEYAMA, Hideyuki TAMAKI, Hiroyuki KUSADA, Yoichi KAMAGATA
-
Publication number: 20240035002Abstract: The invention relates to a method for purifying an adenovirus comprising (a) providing a liquid sample comprising adenovirus, (b) clarifying said sample by depth filtration, (c) performing anion exchange chromatography comprising the steps of (i) directly applying the clarified sample of (b) to an anion exchange column, (ii) eluting adenovirus from the anion exchange column to provide an eluate. The invention also relates to adenovirus produced from said methods, and to compositions comprising same.Type: ApplicationFiled: December 10, 2021Publication date: February 1, 2024Inventors: Alexander DOUGLAS, Carina Citra Dewi JOE
-
Publication number: 20240035003Abstract: Methods for the production of adenoviruses which are suitable for use in a vaccine, and methods for increasing the yield of adenoviruses during production. These methods include adding an adenovirus to a cell population in culture; culturing the cell population under conditions which are permissive for infection of the cell population with the adenovirus to provide a cell population comprising adenovirus-infected cells; culturing the cell population comprising adenovirus-infected cells under conditions which are permissive for replication of the adenovirus; and harvesting the adenovirus from the culture.Type: ApplicationFiled: December 10, 2021Publication date: February 1, 2024Inventors: JINLIN JIANG, NICOLE BLECKWENN, RAGHAVAN VENKAT, DANIEL PAPPAS, BENJAMIN RUSH, GEORGE CHACKO
-
Publication number: 20240035004Abstract: The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of fermentation of metabolically engineered cells. The present invention describes new sucrose permease polypeptides, and their applications. The present invention also describes a metabolically engineered cell for the production of a glycosylated product using the novel sucrose permease polypeptides. Furthermore, the present invention provides a method for the production of a glycosylated product by a cell using the novel sucrose permease polypeptides as well as the purification of said glycosylated product from the cultivation.Type: ApplicationFiled: December 17, 2021Publication date: February 1, 2024Inventors: Joeri Beauprez, Katarzyna Ciesielska, Nausicaä Lannoo, Kristof Vandewalle, Annelies Vercauteren
-
Publication number: 20240035005Abstract: The present invention relates to variants of a parent lipase having reduced odor generation and/or wash performance. The present invention also relates to compositions comprising a lipase variant of the invention, methods and uses of the variants and compositions of the invention, polynucleotides, constructs, expression vectors and host cells comprising the polynucleotide of the invention and methods of producing the lipase variant of the invention.Type: ApplicationFiled: October 28, 2021Publication date: February 1, 2024Applicant: Novozymes A/SInventors: Sune Fang Christensen, Vibeke Svovgaard Nielsen, Lone Baunsgaard, Jesper Vind, Lars Iversen, Matias Emil Moses, Cesar Lene Bjorg, PengFei Tian
-
Publication number: 20240035006Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA or RNA-targeting systems comprising a novel DNA or RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.Type: ApplicationFiled: November 14, 2022Publication date: February 1, 2024Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, University of Tokyo, The United States of America, as Represented by the Secretary Dept of Health and Human ServicesInventors: Takashi Yamano, Hiroshi Nishimasu, Bernd Zetsche, Ian Slaymaker, Yinqing Li, Iana Fedorova, Kira Makarova, Linyi Gao, Eugene Koonin, Feng Zhang, Osamu Nureki
-
Publication number: 20240035007Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems.Type: ApplicationFiled: December 27, 2022Publication date: February 1, 2024Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, University of Tokyo, President and Fellows of Harvard CollegeInventors: Silvana KONERMANN, Alexandro TREVINO, Mark BRIGHAM, Fei RAN, Patrick HSU, Chie-yu LIN, Osamu NUREKI, Hiroshi NISHIMASU, Ryuichiro ISHITANI, Feng ZHANG
-
Publication number: 20240035008Abstract: Genome editing tools for use in systems designed to deliver large genetic elements are disclosed herein. A genome editing system is described, which includes i) an R2 element enzyme or other non-LTR site specific retrotransposon element and ii) a payload RNA, wherein the payload RNA comprises an insertion region and optionally one or more of a 5? homology region, a 3? homology region, and a protein binding element, wherein the insertion region comprises a template for a small or large nucleic acid insertion into the genome, and wherein the R2 element enzyme or other non-LTR site specific retrotransposon element comprises a targeting domain, a reverse transcriptase domain, and a nickase domain. Also disclosed are cells edited using such a genome editing system, methods for editing a genome, and compositions comprising cells edited with this genomic editing system.Type: ApplicationFiled: April 17, 2023Publication date: February 1, 2024Inventors: Omar Abudayyeh, Jonathan Gootenberg, Lukas Villiger, Justin Lim, Christopher W. Fell
-
Publication number: 20240035009Abstract: The present disclosure provides one or more engineered nucleases and systems, compositions, and methods thereof, wherein the one or more engineered nucleases can be used to effect binding, cleaving, and/or editing a target polynucleotide sequence. The one or more engineered nucleases can be engineered variants of a small CRISPR/Cas protein.Type: ApplicationFiled: July 7, 2023Publication date: February 1, 2024Inventors: Xiao Yang, Lei S. Qi, Vincent Cutillas, Gabriella Alvarez, Tabitha Tcheau, Daniel Hart
-
Publication number: 20240035010Abstract: The present invention relates to variant polypeptides, methods of preparing the variant polypeptides, processes for characterizing the variant polypeptides, compositions and cells comprising the variant polypeptides, and methods of using the variant polypeptides. The invention further relates to complexes comprising the variant polypeptides, methods of producing the complexes, processes for characterizing the complexes, cells comprising the complexes, and methods of using the complexes.Type: ApplicationFiled: July 21, 2023Publication date: February 1, 2024Inventors: Lauren E. Alfonse, Shaorong Chong, Anthony James Garrity, Brendan Jay Hilbert, Quinton Norman Wessells
-
Publication number: 20240035011Abstract: The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced specificity and/or efficiency of indel formation, when compared to the first-generation meganuclease HBV 11-12x.26. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or hepatocellular carcinoma.Type: ApplicationFiled: September 12, 2023Publication date: February 1, 2024Applicant: Precision BioSciences, Inc.Inventors: James Jefferson Smith, Janel Lape, Victor Bartsevich, Hui Li
-
Publication number: 20240035012Abstract: Provided are engineered ACE2 oligomers and compositions comprising the oligomers. Also provided are compositions and methods for treating or preventing coronavirus infection and detecting coronavirus.Type: ApplicationFiled: August 23, 2021Publication date: February 1, 2024Inventors: Bobo Dang, Liang Guo, Wenwen Bi, Mengjiao Li
-
Publication number: 20240035013Abstract: Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer.Type: ApplicationFiled: October 19, 2022Publication date: February 1, 2024Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: Augustus O. OKHAMAFE, Sean M. BELL, G. Nick ZECHERLE, Kris ANTONSEN, Yanhong ZHANG, Kieu Ly TRAN, Paul A. FITZPATRICK, Emil D. KAKKIS, Michel Claude VELLARD, Daniel J. WENDT, Mubarack MUTHALIF
-
Publication number: 20240035014Abstract: Described herein are polyhedral, three-dimensional tunable nanocages assembled with a multimeric protein covalently linked to a polynucleotide handle and a DNA origami base assembly including sequences complementary to the polynucleotide handles, wherein the polynucleotide handle and the complementary sequences hybridize to for double-stranded DNA helices.Type: ApplicationFiled: October 12, 2023Publication date: February 1, 2024Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITYInventors: Nicholas Stephanopoulos, Yang Xu
-
Publication number: 20240035015Abstract: A feedback system that identifies characteristics of one or more cells being grown on a metasurface and utilizes the characteristics to initiate and adjust a field applied to the metasurface to control adhesion of the cells to and from the metasurface. The metasurface includes a plurality of structures whose resonances (localized or non-localized) have a wavelength range of 250 nm-3 microns. In one embodiment, the system leverages machine learning to automatically identify characteristics of the one or more cells or the metasurface and adjust the parameters of the field based on the characteristics. Sensors are utilized during the application of the field to monitor characteristics of the one or more cells or the metasurface and parameters of the field. Based on the measurements, parameters of the field can be adjusted to achieve the desired effect on the detachment of the cells.Type: ApplicationFiled: July 28, 2022Publication date: February 1, 2024Inventors: Krishnan Thyagarajan, Christopher Somogyi
-
Publication number: 20240035016Abstract: Compositions and methods for isolating and detecting nucleic acid in a biological sample are provided. The compositions and methods utilize a modified solid support comprising an amine or amide group.Type: ApplicationFiled: April 28, 2023Publication date: February 1, 2024Inventors: Alex I. KUTYAVIN, Kevin P. LUND, Michael REED, Cameron J. NAKATANI, Oliver Z. NANASSY, Richard J. LEUZZI
-
Publication number: 20240035017Abstract: Some aspects of this disclosure provide compositions, strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins capable of inducing a cytosine (C) to guanine (G) change in a nucleic acid (e.g., genomic DNA) are provided. In some embodiments, fusion proteins of a nucleic acid programmable DNA binding protein (e.g., Cas9) and nucleic acid editing proteins or protein domains, e.g., deaminase domains, polymerase domains, and/or base excision enzymes are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of a nucleic acid programmable DNA binding protein (e.g., Cas9), and nucleic acid editing proteins or domains, are provided.Type: ApplicationFiled: November 28, 2022Publication date: February 1, 2024Applicant: President and Fellows of Harvard CollegeInventors: David R. Liu, Luke W. Koblan
-
Publication number: 20240035018Abstract: Building DNA strands at a high rate that are suitable for data storage. Methods include using DNAzyme and utilizing libraries of pre-prepared oligos. A system for the DNA strand synthesis includes: a DNA symbol library comprising a number of single strand oligo symbols; a DNA linker library comprising a first set of single strand oligo linkers and a second set of single strand oligo linkers; and a DNAzyme library comprising a number of DNAzymes. An S1 end of a first DNAzyme is adapted to join the S1 end of a symbol and an S2 end of the first DNAzyme is adapted to join an S2 end of a first linker, and an S1 end of a second DNAzyme is adapted to join an S1 end of a second linker and an S2 end of the second DNAzyme is adapted to join an S2 end of the symbol.Type: ApplicationFiled: July 29, 2022Publication date: February 1, 2024Inventors: Gemma Roselle MENDONSA, Walter R. EPPLER
-
Publication number: 20240035019Abstract: Disclosed herein are compositions and methods for sequencing, analyzing, and utilizing samples such as single samples. Also disclosed herein are compositions and methods for matching together two or more sequences from a sample. Also disclosed herein are compositions and methods for expressing and screening molecules of interest.Type: ApplicationFiled: June 28, 2018Publication date: February 1, 2024Inventors: William H. Robinson, Yann Chong Tan, Jeremy Sokolove
-
Publication number: 20240035020Abstract: The present invention relates to a synthetic library of vvthumanised antigen specific binding molecules derived from a member of a species in the Elasmobranchii subclass, processes for the production thereof and specific antigen specific binding molecules isolated from said library. The present invention also relates to the multi-domain specific binding molecules comprising humanised Ig-like Novel Antigen Receptor variable domains (VNARs). Specific binding domains that bind to Tumour Necrosis Factor alpha (TNF?) are also provided.Type: ApplicationFiled: September 15, 2022Publication date: February 1, 2024Inventors: Caroline Jane BARELLE, Marina KOVALEVA, Laura Ann FERGUSON, Obinna Chukwuemeka UBAH, Andrew Justin Radcliffe PORTER
-
Publication number: 20240035021Abstract: Provided are methods and compositions for generating a deletion library, and methods and compositions for generating and identifying a defective interfering particle (DIP). Also provided are transposon cassettes. A subject method can include: inserting a transposon cassette comprising a target sequence for a sequence specific DNA endonuclease into a population of circular target DNAs to generate a population of transposon-inserted circular target DNAs; contacting the population of transposon-inserted circular target DNAs with the sequence specific DNA endonuclease to generate a population of cleaved linear target DNAs; contacting the population of cleaved linear target DNAs with one or more exonucleases to generate a population of deletion DNAs; and circularizing the deletion DNAs to generate a library of circularized deletion DNAs. The population of circular target DNAs can include viral genomic DNA. Also provided ae human immunodeficiency virus (HIV) deletion mutants, e.g.Type: ApplicationFiled: February 20, 2023Publication date: February 1, 2024Inventors: Leor S. Weinberger, Timothy J. Notton
-
Publication number: 20240035022Abstract: Provided are compositions and methods for expressing a plurality of target polypeptides at a high level in mammalian host cells. Each target polypeptide is encoded on a polynucleotide comprising a nucleotide sequence encoding a unique cell surface marker polypeptide and a nucleotide sequence encoding a unique target polypeptide, wherein both the nucleotide sequence encoding the unique cell surface marker polypeptide and the nucleotide sequence encoding the unique target polypeptide are transcribed on the same mRNA. Each mammalian host cell comprises a plurality of different polynucleotides, such that the cell is capable of expressing a plurality of unique target polypeptides and a plurality of unique cell surface marker polypeptides. In certain embodiments, the plurality of unique cell surface marker polypeptides are variants of CD52. The compositions and methods are useful for expressing multimeric target proteins, e.g., crossover dual-variable domain (CODV) triabodies.Type: ApplicationFiled: May 10, 2023Publication date: February 1, 2024Inventors: Victor R. Cairns, David Reczek, Jason Vitko
-
Publication number: 20240035023Abstract: The present invention discloses a computer-implemented method for engineering fluorinase enzymes towards the synthesis of fluorophenyl compounds. Limited or no mechanistic details of fluorinase enzymes have hindered progress in understanding their catalytic mechanisms for synthesizing synthetic organofluorine compounds. Through a comprehensive computational screening process, specific methionine-sulfonium phenyl substrates, including [(3S)-3-amino-3-carboxypropyl][2,5-difluoro-4-(4-methoxy-2,4-dioxobutyl)phenyl]methylsulfonium, were designed and optimized using quantum chemical optimization techniques. This methodology uncovers crucial information on F— ion attack conformation and the catalytic mechanism of the substrate, leading to the formation of Methyl 3-oxo-4-(2,4,5-trifluorophenyl)butanoate. Furthermore, a protein sequence and 3D modeling-based enzyme screening process was employed to identify the most suitable enzyme for this substrate.Type: ApplicationFiled: June 26, 2023Publication date: February 1, 2024Applicant: Kcat Enzymatic Private LimitedInventors: Pravin Kumar R, Gladstone Sigamani G, Roopa L, Naveen B K, Anuj J Shetty, Likith M
-
Publication number: 20240035024Abstract: The present invention relates to innovative means of generating sequence-linked DNA fragments and subsequent uses of such linked DNA fragments for de novo haplotype-resolved whole genome mapping and massively parallel sequencing. In various embodiments described herein, the methods of the invention relate to methods of generating linked-paired end nucleic acid fragments sharing common linker nucleic acid sequences using a computationally-designed sgRNA library together with a nicking RNA-guided endonuclease, methods of analyzing the nucleotides sequences from the linked-paired-end sequenced fragments, and methods of de novo whole genome mapping. Thus, the methods of this invention allow establishing sequence contiguity across the whole genome, and achieving high-quality, low-cost de novo assembly of complex genomes.Type: ApplicationFiled: October 15, 2021Publication date: February 1, 2024Inventors: Ming Xiao, Lahari Uppuluri
-
Publication number: 20240035025Abstract: The present disclosure relates, in part, to circular RNAs and engineered variants thereof.Type: ApplicationFiled: October 3, 2023Publication date: February 1, 2024Inventors: Matthew ANGEL, Christopher ROHDE, Aisha SVIHLA
-
Publication number: 20240035026Abstract: The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.Type: ApplicationFiled: September 28, 2021Publication date: February 1, 2024Inventors: Hans E. Huber, David Blakey, Jon Voutila, Monika Krampert, Markus Hossbach
-
Publication number: 20240035027Abstract: This disclosure relates to novel PMS2 targeting sequences. Novel PMS2 targeting oligonucleotides for the treatment of a trinucleotide repeat disease or disorder are also provided.Type: ApplicationFiled: May 3, 2023Publication date: February 1, 2024Inventors: Anastasia Khvorova, Daniel O'Reilly, Chantal Ferguson, Jillian Belgrad
-
Publication number: 20240035028Abstract: The present disclosure relates to compositions of matter and assay methods used to detect one or more target nucleic acids of interest in a sample. The compositions and methods provide signal boost upon detection of target nucleic acids of interest in less than one minute and in some instances instantaneously at ambient temperatures down to 16° C. or less, without amplification of the target nucleic acids yet allowing for massive multiplexing, high accuracy and minimal non-specific signal generation.Type: ApplicationFiled: August 16, 2023Publication date: February 1, 2024Inventors: Anurup Ganguli, Ashish Pandey, Ariana Mostafa, Jacob Berger
-
Publication number: 20240035029Abstract: The present disclosure relates to dsRNAs targeting LPA mRNA and modulating Lp(a) plasma levels, and methods of treating one or more conditions associated with LPA gene expression.Type: ApplicationFiled: October 15, 2021Publication date: February 1, 2024Inventors: Bodo BRUNNER, Bertrand FROTTIER, Etienne GUILLOT, Mike HELMS, Armin HOFMEISTER, Kerstin JAHN-HOFMANN, Sabine SCHEIDLER
-
Publication number: 20240035030Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: June 7, 2023Publication date: February 1, 2024Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Lloyd B. Jeffs, Lorne R. Palmer
-
Publication number: 20240035031Abstract: This disclosure provides compositions and methods of using these compositions to mediate a targeted trans-splicing event on a pre-mRNA in a cell.Type: ApplicationFiled: August 15, 2023Publication date: February 1, 2024Inventor: Jacob Borrajo
-
Publication number: 20240035032Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.Type: ApplicationFiled: February 27, 2023Publication date: February 1, 2024Applicant: Hoffmann-La roche Inc.Inventors: Hassan JAVANBAKH, Søren OTTOSEN, Morten LINDOW
-
Publication number: 20240035033Abstract: Provided is a method for prevention and treatment of age-related macular degeneration through the suppression of cathepsin S expression, and retinal pigment epithelial cells in which cathepsin S is knocked down can be usefully used as a target for preventing or treating dry and wet age-related macular degenerations, in that the expression level of inflammatory cytokines and complement activity are reduced even under oxidative stress conditions, and the retinal pigment epithelial cells are not only more effective in suppressing complement activity than NF-?B inhibitors, but also suppress intracellular neovascularization and tube formation.Type: ApplicationFiled: July 28, 2023Publication date: February 1, 2024Applicant: CHUNG-ANG UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventor: Jee Taek KIM
-
Publication number: 20240035034Abstract: The present invention provides an isolated nucleic acid comprising more than 220 bp, one or more copy of a sequence selected from the group of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and a CpG Observed over Estimated ratio (O/E ratio) larger than 0.Type: ApplicationFiled: December 2, 2021Publication date: February 1, 2024Inventors: Ralph GRAND, Marlena LUEBKE, Dirk Schuebeler
-
Publication number: 20240035035Abstract: The present disclosure provides small hairpin nucleic acid molecules capable of stimulating interferon production. The nucleic acid molecules of the present disclosure has a double-stranded section of less than 19 base pairs and at least one blunt end. In certain embodiments, the molecule comprises a 5?-triphosphate or a 5?-diphosphate.Type: ApplicationFiled: December 9, 2021Publication date: February 1, 2024Inventors: Anna Marie Pyle, Akiko Iwasaki, Tianyang Mao
-
Publication number: 20240035036Abstract: The invention relates to a polynucleotide flmG which encodes Flagellin Modification Protein (FlmG) having a glycosyltransferase activity as well as a recombinant expression vector for bacterial expression comprising the polynucleotide flmG of the invention. Also provided is a prokaryotic protein glycosylation kit for soluble O-based glycosylation comprising a bacterial Gram-negative host expressing at least one copy of the recombinant expression vector of the invention and a process for O-glycosylation of soluble proteins of interest.Type: ApplicationFiled: October 15, 2021Publication date: February 1, 2024Inventors: Patrick VIOLLIER, Silvia ARDISSONE, Nicolas KINT
-
Publication number: 20240035037Abstract: Recombinant expression vectors are disclosed that include a control sequence for recombinant expression of proteins of interest; the control sequence combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence or a human cytomegalovirus (huCMV) intron A sequence. Some of the vectors are useful for inducible expression. Some of the vectors contain a 5? PiggyBac ITR and a 3? PiggyBac ITR to promote genomic integration into a host cell chromosome. A method of selecting a stable production cell line for manufacturing a protein of interest is also disclosed. Also disclosed are mammalian host cells comprising the inventive recombinant expression vectors and methods of producing a protein of interest, in vitro, involving the mammalian host cell.Type: ApplicationFiled: July 3, 2023Publication date: February 1, 2024Applicant: Just-Evotec Biologics, Inc.Inventors: Jeffrey T. McGrew, James Joyce McDermott, Sherman Ku
-
Publication number: 20240035038Abstract: The invention relates to C. acnes strains carrying DNA vectors for the production of recombinant C. acnes phages. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a template for recombination with C. acnes phage genome leading to the insertion of a gene of interest, for the production of recombinant phages that can lead to the transgene expression into C. acnes infected by the recombinant phage. The invention encompasses, C. acnes strains containing these vectors, C. acnes recombinant phages and methods of using these recombinant phages.Type: ApplicationFiled: September 29, 2023Publication date: February 1, 2024Inventors: Aymeric LEVEAU, Inès CANADAS BLASCO, Aurélie MATHIEU, Antoine DECRULLE
-
Publication number: 20240035039Abstract: Recombinant DNA molecules and constructs are provided that are useful for modulating gene expression in plants. One or more expression cassette(s) of a recombinant DNA molecule or construct may be excised from transgenic plants following transformation by the presence of flanking site-specific recombination sites in the recombinant DNA molecule or construct by expression of a recombinase enzyme encoded by the recombinant DNA molecule or construct. Such a recombinase system may be used to remove such expression cassette(s) from plants transformed with the recombinant DNA construct or vector. The recombinase transgene may be operably linked to a tissue-preferred or tissue-specific promoter for autoexcision in transformed plants without crossing to a different transgenic line expressing the recombinase.Type: ApplicationFiled: October 19, 2021Publication date: February 1, 2024Inventors: PokChun Jennifer To, Zrir Vaghchhipawala, Xudong Ye
-
Publication number: 20240035040Abstract: The present invention is in the field of plant molecular biology and provides methods for production of high expressing constitutive promoters and the production of plants with enhanced constitutive expression of nucleic acids wherein nucleic acid expression enhancing nucleic acids (NEENAs) are functionally linked to the promoters and/or introduced into plants.Type: ApplicationFiled: July 24, 2023Publication date: February 1, 2024Inventors: Josef Martin Kuhn, Linda Patricia Loyall, Malte Siebert, Elke Duwenig
-
Publication number: 20240035041Abstract: The disclosure describes a transgenic dicot or monocot plant having bovine milk protein(s) (e.g., bovine casein) and methods of producing the transgenic dicot or monocot plant containing bovine milk protein(s). These transgenic dicot or monocot plants can express and produce bovine milk protein(s) (e.g., bovine casein). The methods involve introducing a recombinant DNA construct expressing a bovine milk protein into a dicot or monocot plant, obtaining the dicot or monocot plant containing the bovine milk protein(s) from a recombinant DNA construct, cultivating and harvesting the transgenic dicot or monocot plant, and extracting and purifying the bovine milk protein(s) (e.g., bovine casein) from transgenic dicot or monocotyledonous plants. The disclosure also describes food compositions comprising milk proteins produced using the transgenic dicot or monocot plants described herein.Type: ApplicationFiled: December 15, 2022Publication date: February 1, 2024Inventors: Magi EL-RICHANI, Shu LI
-
Publication number: 20240035042Abstract: The present disclosure provides the identification of genes involved in sucker growth in tobacco. Also provided are promoters that are preferentially active in tobacco axillary buds. Also provided are modified tobacco plants comprising reduced or no sucker growth. Also provided are methods and compositions for producing modified tobacco plants comprising reduced or no sucker growth.Type: ApplicationFiled: September 28, 2023Publication date: February 1, 2024Applicant: ALTRIA CLIENT SERVICES LLCInventors: Dongmei XU, Chengalrayan KUDITHIPUDI, Yanxin SHEN, Jaemo YANG, Jesse FREDERICK, James STRICKLAND
-
Publication number: 20240035043Abstract: An application of maize raffinose synthase (ZrnRAFS) gene in maize to improve heat stress tolerance of crops is provided. The nucleotide sequence of the ZrnRAFS gene is shown in SEQ ID NO: 1, and the protein sequence encoded by the ZrnRAFS gene is shown in SEQ ID NO: 2. The ZrnRAFS gene is overexpressed in plants, raffinose is synthesized by using sucrose and galactinol, which increases the content of raffinose in maize leaves and improves the heat stress tolerance of maize.Type: ApplicationFiled: July 25, 2023Publication date: February 1, 2024Inventors: TianYong Zhao, Ying Liu, Dong Yan, Yumin Zhang
-
Publication number: 20240035044Abstract: Provided are a lentivirus packaging vector and a packaging method thereof. The lentivirus packaging vector contains a first LTR, a reversely inserted gene expression cassette and a second LTR, wherein the first LTR is positioned upstream of the reversely inserted gene expression cassette in the direction of viral genome expression; the second LTR is positioned downstream of the reversely inserted gene expression cassette in the direction of viral genome expression; the gene expression cassette contains a promoter, a repressible operon, a gene of interest and a polyadenylation signal, which are connected in sequence; and in the presence of a repressor, the repressible operon represses the expression of the gene of interest.Type: ApplicationFiled: December 6, 2021Publication date: February 1, 2024Inventors: Xinglin YANG, Qingrui YOU, Jiali YANG, Peimin MA, Guodong JIA, Oudong PAN
-
Publication number: 20240035045Abstract: Provided herein are compositions and methods comprising modified adeno-associated virus (AAV) capsids. Also provided are methods of utilizing the provided compositions and methods as ocular therapeutics.Type: ApplicationFiled: May 10, 2023Publication date: February 1, 2024Inventors: Shengjiang LIU, Haifeng CHEN, Xiaoming GONG
-
Publication number: 20240035046Abstract: In some aspects, the disclosure relates to methods for improving titer and yield of viral vector production. In some embodiments, the methods comprise transient silencing of transgene expression during packaging of a viral vector.Type: ApplicationFiled: August 15, 2023Publication date: February 1, 2024Applicant: University of MassachusettsInventors: Jun Xie, Guangping Gao
-
Publication number: 20240035047Abstract: Presented herein are technologies and methods for improved production of AAV vectors.Type: ApplicationFiled: October 6, 2023Publication date: February 1, 2024Inventors: Matthias Charles Jerome HEBBEN, Jing LIAO, Carmen WU, Wilhad Hans REUTER, Thomas Matthew EDWARDS